Research ArticleAlzheimer’s Disease

Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer’s disease

See allHide authors and affiliations

Science Translational Medicine  28 Aug 2019:
Vol. 11, Issue 507, eaav6221
DOI: 10.1126/scitranslmed.aav6221

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Boosting TREM2 in AD

Alzheimer’s disease (AD) is a devastating neurodegenerative disorder, and clinical trials using anti-amyloid treatments have failed. New therapeutic targets are therefore required. Recent genetic studies have revealed a major role for microglia in disease progression. Loss-of-function mutations in TREM2 dramatically increase the risk for late onset AD, therefore boosting that TREM2 function may be a useful therapeutic strategy. Ewers et al. examined whether increased TREM2 is protective in patients with AD. They found that higher concentrations of soluble TREM2 in cerebrospinal fluid were associated with reduced memory decline and hippocampal shrinkage in patients with AD. Thus, therapeutic strategies that boost TREM2 signaling may be beneficial in AD.

View Full Text